

.....  
(Original Signature of Member)

115TH CONGRESS  
2D SESSION

# H. R.

---

To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.

---

## IN THE HOUSE OF REPRESENTATIVES

Mr. CARTER of Georgia introduced the following bill; which was referred to the Committee on \_\_\_\_\_

---

# A BILL

To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited at the “Abuse Deterrent Ac-  
5 cess Act of 2018”.

1 **SEC. 2. STUDY ON ABUSE-DETERRENT OPIOID FORMULA-**  
2 **TIONS ACCESS BARRIERS UNDER MEDICARE.**

3 (a) IN GENERAL.—Not later than 180 days after the  
4 date of the enactment of this Act, the Secretary of Health  
5 and Human Services shall conduct a study and submit to  
6 Congress a report on the adequacy of access to abuse-de-  
7 terrent opioid formulations for individuals with chronic  
8 pain enrolled in an MA-PD plan under part C of title  
9 XVIII of the Social Security Act or a prescription drug  
10 plan under part D of such title of such Act, taking into  
11 account any barriers preventing such individuals from ac-  
12 cessing such formulations under such MA-PD or part D  
13 plans, such as cost-sharing tiers, fail-first requirements,  
14 and prior authorization requirements.

15 (b) DEFINITION OF ABUSE-DETERRENT OPIOID FOR-  
16 MULATION.—In this section, the term “abuse-deterrent  
17 opioid formulation” means an opioid with certain abuse-  
18 deterrent properties, such as physical or chemical barriers,  
19 agonist or antagonist combinations, aversion properties,  
20 delivery system mechanisms, or other features designed to  
21 prevent abuse of such opioid.